Genetic mechanisms of critical illness in COVID-19
- PMID: 33307546
- DOI: 10.1038/s41586-020-03065-y
Genetic mechanisms of critical illness in COVID-19
Abstract
Host-mediated lung inflammation is present1, and drives mortality2, in the critical illness caused by coronavirus disease 2019 (COVID-19). Host genetic variants associated with critical illness may identify mechanistic targets for therapeutic development3. Here we report the results of the GenOMICC (Genetics Of Mortality In Critical Care) genome-wide association study in 2,244 critically ill patients with COVID-19 from 208 UK intensive care units. We have identified and replicated the following new genome-wide significant associations: on chromosome 12q24.13 (rs10735079, P = 1.65 × 10-8) in a gene cluster that encodes antiviral restriction enzyme activators (OAS1, OAS2 and OAS3); on chromosome 19p13.2 (rs74956615, P = 2.3 × 10-8) near the gene that encodes tyrosine kinase 2 (TYK2); on chromosome 19p13.3 (rs2109069, P = 3.98 × 10-12) within the gene that encodes dipeptidyl peptidase 9 (DPP9); and on chromosome 21q22.1 (rs2236757, P = 4.99 × 10-8) in the interferon receptor gene IFNAR2. We identified potential targets for repurposing of licensed medications: using Mendelian randomization, we found evidence that low expression of IFNAR2, or high expression of TYK2, are associated with life-threatening disease; and transcriptome-wide association in lung tissue revealed that high expression of the monocyte-macrophage chemotactic receptor CCR2 is associated with severe COVID-19. Our results identify robust genetic signals relating to key host antiviral defence mechanisms and mediators of inflammatory organ damage in COVID-19. Both mechanisms may be amenable to targeted treatment with existing drugs. However, large-scale randomized clinical trials will be essential before any change to clinical practice.
Comment in
-
Replication of LZTFL1 Gene Region as a Susceptibility Locus for COVID-19 in Latvian Population.Virol Sin. 2021 Oct;36(5):1241-1244. doi: 10.1007/s12250-021-00448-x. Epub 2021 Oct 20. Virol Sin. 2021. PMID: 34668132 Free PMC article. No abstract available.
Similar articles
-
TYK2, IFITM3, IFNAR2 and OAS3 single-nucleotide polymorphisms among severe COVID-19 ICU patients in Morocco.Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241257241. doi: 10.1177/03946320241257241. Int J Immunopathol Pharmacol. 2024. PMID: 38760017 Free PMC article.
-
A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance.Elife. 2021 Aug 17;10:e69719. doi: 10.7554/eLife.69719. Elife. 2021. PMID: 34402426 Free PMC article.
-
Proteomic profiling identifies novel proteins for genetic risk of severe COVID-19: the Atherosclerosis Risk in Communities Study.Hum Mol Genet. 2022 Jul 21;31(14):2452-2461. doi: 10.1093/hmg/ddac024. Hum Mol Genet. 2022. PMID: 35212764 Free PMC article.
-
Genome-wide association studies of COVID-19: Connecting the dots.Infect Genet Evol. 2022 Dec;106:105379. doi: 10.1016/j.meegid.2022.105379. Epub 2022 Oct 21. Infect Genet Evol. 2022. PMID: 36280088 Free PMC article. Review.
-
Hypotheses and facts for genetic factors related to severe COVID-19.World J Virol. 2021 Jul 25;10(4):137-155. doi: 10.5501/wjv.v10.i4.137. World J Virol. 2021. PMID: 34367930 Free PMC article. Review.
Cited by
-
Polygenic prediction of human longevity on the supposition of pervasive pleiotropy.Sci Rep. 2024 Aug 28;14(1):19981. doi: 10.1038/s41598-024-69069-0. Sci Rep. 2024. PMID: 39198552
-
UKB.COVID19: an R package for UK Biobank COVID-19 data processing and analysis.F1000Res. 2024 Jul 26;10:830. doi: 10.12688/f1000research.55370.2. eCollection 2021. F1000Res. 2024. PMID: 39193262 Free PMC article.
-
Association between TMPRSS2 rs2070788 polymorphism and COVID-19 severity: a case-control study in multiple cities of Iran.Front Med (Lausanne). 2024 Aug 12;11:1425916. doi: 10.3389/fmed.2024.1425916. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39188881 Free PMC article.
-
No evidence that ACE2 or TMPRSS2 drive population disparity in COVID risks.BMC Med. 2024 Aug 26;22(1):337. doi: 10.1186/s12916-024-03539-0. BMC Med. 2024. PMID: 39183295 Free PMC article.
-
Premature aging effects on COVID-19 pathogenesis: new insights from mouse models.Sci Rep. 2024 Aug 24;14(1):19703. doi: 10.1038/s41598-024-70612-2. Sci Rep. 2024. PMID: 39181932 Free PMC article.
References
-
- Dorward, D. A. et al. Tissue-specific immunopathology in fatal COVID-19. Am. J. Respir. Crit. Care Med. https://doi.org/10.1164/rccm.202008-3265OC (2020).
-
- The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19 — preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2021436 (2020).
Publication types
MeSH terms
Substances
Grants and funding
- MR/K01417X/1/MRC_/Medical Research Council/United Kingdom
- MR/M00869X/2/MRC_/Medical Research Council/United Kingdom
- MC_PC_19056/MRC_/Medical Research Council/United Kingdom
- 104036/Z/14/Z/WT_/Wellcome Trust/United Kingdom
- G1001253/MRC_/Medical Research Council/United Kingdom
- MR/L501542/1/MRC_/Medical Research Council/United Kingdom
- MR/R026408/1/MRC_/Medical Research Council/United Kingdom
- MR/N02995X/1/MRC_/Medical Research Council/United Kingdom
- MC_PC_20004/MRC_/Medical Research Council/United Kingdom
- MR/S006753/1/MRC_/Medical Research Council/United Kingdom
- 216767/Z/19/Z/WT_/Wellcome Trust/United Kingdom
- G0701075/MRC_/Medical Research Council/United Kingdom
- G0901254/MRC_/Medical Research Council/United Kingdom
- MC_PC_19026/MRC_/Medical Research Council/United Kingdom
- MC_EX_MR/M009203/1/MRC_/Medical Research Council/United Kingdom
- G-0907/PUK_/Parkinson's UK/United Kingdom
- 205228/Z/16/Z/WT_/Wellcome Trust/United Kingdom
- 103258/Z/13/A/WT_/Wellcome Trust/United Kingdom
- MC_PC_19059/MRC_/Medical Research Council/United Kingdom
- MC_UU_00007/15/MRC_/Medical Research Council/United Kingdom
- MC_UU_12008/1/MRC_/Medical Research Council/United Kingdom
- G-1307/PUK_/Parkinson's UK/United Kingdom
- MC_UU_12014/9/MRC_/Medical Research Council/United Kingdom
- MR/S032304/1/MRC_/Medical Research Council/United Kingdom
- MR/M009203/1/MRC_/Medical Research Council/United Kingdom
- MR/J004758/1/MRC_/Medical Research Council/United Kingdom
- MC_UU_00007/10/MRC_/Medical Research Council/United Kingdom
- MR/P015514/1/MRC_/Medical Research Council/United Kingdom
- MC_PC_19025/MRC_/Medical Research Council/United Kingdom
- MR/R026408/1/WT_/Wellcome Trust/United Kingdom
- 215091/Z/18/Z/WT_/Wellcome Trust/United Kingdom
- 109965/Z/15/Z/WT_/Wellcome Trust/United Kingdom
- MC_PC_14089/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical